The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study.
Brian I. Rini
No relevant relationships to disclose
Cezary Szczylik
No relevant relationships to disclose
Nizar M. Tannir
No relevant relationships to disclose
Piotr Koralewski
No relevant relationships to disclose
Piotr Tomczak
No relevant relationships to disclose
Andrzej Deptala
No relevant relationships to disclose
Karolyn Kracht
No relevant relationships to disclose
Yu-Nien Sun
No relevant relationships to disclose
Markus Puhlmann
No relevant relationships to disclose
Bernard Escudier
No relevant relationships to disclose